ASCO 2023 | Novel immunotherapy approaches in metastatic head and neck cancer
Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, gives an overview of developments in utilizing immunotherapy for patients with metastatic head and neck cancer. The combination of PD-1 and VEGF inhibitors such as pembrolizumab and cabozantinib is a promising strategy, and findings from the LEAP-010 trial (NCT04199104) of pembrolizumab with lenvatinib further demonstrated the efficacy of this combination. Cetuximab with ficlatuzumab has additionally been assessed in a Phase II trial (NCT03422536) in patients with HPV-negative head and neck cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
